TG Therapeutics
TGTX
77 hedge funds and large institutions have $208M invested in TG Therapeutics in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 22 increasing their positions, 26 reducing their positions, and 18 closing their positions.
17% more capital invested
Capital invested by funds: $178M → $208M (+$30M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
15% less funds holding
Funds holding: 91 → 77 (-14)
15% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 26
72% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 18
83% less call options, than puts
Call options by funds: $114K | Put options by funds: $653K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$639K |
| 2 |
CCI
Columbus Circle Investors
|
+$370K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$355K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$349K |
| 5 |
Morgan Stanley
New York
|
+$338K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$9.14M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$1.76M |
| 3 |
Millennium Management
New York
|
-$1.2M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.06M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$750K |
TGTX Hedge Fund Activity: Q3 2016 in Review
77 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q3 2016, worth a combined $208M — up 17% from $178M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of TGTX and 5 opened new positions — a net loss of 13 holders — while 26 trimmed existing stakes and 22 added.
The largest buyer was RA Capital Management, adding an estimated $639K. The largest seller was Pictet Asset Management (UK), exiting entirely with an estimated $9.14M sold.
- 77 institutional investors held TG Therapeutics (TGTX) as of Q3 2016, down from 91 in Q2 2016.
- Funds reported $208M of TG Therapeutics stock for Q3 2016, up 17% quarter-over-quarter.
- 5 funds opened new TG Therapeutics positions in Q3 2016 and 18 closed out, a net change of -13 holders.
- The largest TG Therapeutics buyer in Q3 2016 was RA Capital Management, an estimated $639K added.
- The largest TG Therapeutics seller in Q3 2016 was Pictet Asset Management (UK), an estimated $9.14M sold.
Based on aggregated 13F filings for Q3 2016.